Declining Interest in the Band in Europe

In Europe, the preference for gastric band has declined in favor of Roux-Y-gastric bypass.

After LAGB, band removal was necessary for complications or insufficient weight loss in 24% of patients.

Only half of the patients achieved a more than 50% EWL,

The failure in one out of four patients does not allow proposing the Band as a first-line option for the treatment of obesity.

Amplify’d from www.ncbi.nlm.nih.gov
Obes Surg. 2011 May;21(5):582-7.

Long-term results of a prospective study on laparoscopic adjustable gastric banding for morbid obesity.

Source

Department of Gastrointestinal Surgery, University Hospital Ghent, De Pintelaan 185, 9000 Ghent, Belgium. yves.van.nieuwenhove@ugent.be

Abstract

BACKGROUND:

The objective of this study was to study the long-term outcome of adjustable gastric banding in the treatment of morbid obesity. In Europe, the preference for gastric band has declined in favor of Roux-Y-gastric bypass.

METHODS:

This is a follow-up of a prospective study on a large cohort of patients after laparoscopic gastric banding (LAGB) for morbid obesity.

RESULTS:

Complete data were collected on 656 patients (88%) from a cohort of 745 patients. After a median follow-up of 95 months (range 60-155), the mean BMI dropped from 41.0 ± 7.3 to 33.2 ± 7.1 kg/m², with a 46.2 ± 36.5% excess weight loss (EWL). A more than 50% EWL was achieved in 44% of patients. The band was still in place in 77.1% of patients; conversion to gastric bypass after band removal was carried out in 98 (14.9%) patients, while a simple removal was done in only 52 (7.9%) patients. Band removal was more likely in women and patients with a higher BMI.

CONCLUSIONS:

After LAGB, band removal was necessary for complications or insufficient weight loss in 24% of patients. Nearly half of the patients achieved a more than 50% EWL, but in 88%, a more than 10% EWL was observed. LAGB can achieve an acceptable weight loss in some patients, but the failure in one out of four patients does not allow proposing it as a first-line option for the treatment of obesity.

Read more at www.ncbi.nlm.nih.gov

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s